おかえりなさい
Click “ログイン” to agree to Cointime’s 利用規約 and acknowledge that Cointime’s プライバシーポリシー applies to you.
アカウント登録
Already have an account?
Click “page.Sign up” to agree to Cointime’s <a class="underline" href="#term-of-service">利用規約</a> and acknowledge that Cointime’s a class="underline" href="#privacy-policy">プライバシーポリシー</a> applies to you.
siteでログインする
siteで登録する
あなたのメールアドレス
受信トレイを確認する
Click the link we sent to to sign in.
Click the link we sent to to sign up.
Biostar Technologies
company
About
Biostar Technologies focuses in medical design, transfer of technology, and tech support advising for anti-tumor small chemicals drugs.
- 11 - 50
Details
- Last Funding Type
- Series B
- Industries
- Biotechnology,Life Science,Medical,Pharmaceutical
- Founded date
- Jan 1, 2002
- Number Of Employee
- 11 - 50
- Operating Status
- Active
Beijing Biostar Technologies, Ltd. was incorporated in Haidian Park, Zhongguancun Science and Technology Park, Beijing, in July 2002. The national high-tech led by the team of Chinese scientists in the United States led by Dr. Tang Li and Dr. Qiu Rongguo. The company, focusing on biomedical development, technology and transfer of anti-tumor small molecule chemical drugs, and technical service consulting, pioneered the creation of new anti-cancer drugs for epothilone in China, and its technology is at the international advanced level.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
2
$890M
Biostar Technologies has raised a total of
$890M
in funding over 2 rounds. Their latest funding was raised on
Nov 26, 2020 from a Series E round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Nov 26, 2020 | Series E | $890M | 2 | — | — | Detail |
| Feb 19, 2019 | Series B | — | 1 | — | — | Detail |
Investors
Number of Lead Investors
Number of Investors
—
3
Biostar Technologies is funded by 3 investors.
Chengdu Biocity
and Tianchuang Capital
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
|
— | Series E |
|
|
— | Series E |
|
|
— | Series B |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
